HTG Molecular Diagnostics - HTGM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.63
  • Forecasted Upside: 390.98 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$0.94
▼ -0.07 (-6.92%)
Get New HTG Molecular Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HTGM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HTGM

Analyst Price Target is $4.63
▲ +390.98% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for HTG Molecular Diagnostics in the last 3 months. The average price target is $4.63, with a high forecast of $10.00 and a low forecast of $2.00. The average price target represents a 390.98% upside from the last price of $0.94.

This chart shows the closing price for HTGM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in HTG Molecular Diagnostics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022HC WainwrightLower TargetBuy$3.00 ➝ $2.00N/A
7/22/2022Cantor FitzgeraldLower Target$15.00 ➝ $3.50N/A
5/16/2022HC WainwrightLower TargetNA$4.00 ➝ $3.00N/A
3/30/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/30/2022HC WainwrightLower TargetBuy$9.00 ➝ $4.00N/A
3/30/2022Craig HallumLower TargetBuy$8.00 ➝ $3.00N/A
1/11/2022HC WainwrightReiterated RatingBuy$9.00N/A
1/7/2022Craig HallumUpgradeHold ➝ Buy$5.00 ➝ $8.00N/A
12/23/2021HC WainwrightReiterated RatingBuy$9.00N/A
9/14/2021SVB LeerinkReiterated RatingBuy$10.00N/A
7/21/2021HC WainwrightReiterated RatingBuy$9.00Medium
5/20/2021HC WainwrightLower TargetBuy$11.00 ➝ $9.00Medium
5/14/2021SVB LeerinkLower TargetOutperform$10.00High
5/14/2021HC WainwrightLower TargetBuy$9.00High
11/11/2020SVB LeerinkLower TargetOutperform$2.00 ➝ $1.00High
8/5/2020HC WainwrightReiterated RatingBuy$1.00Medium
6/19/2020HC WainwrightReiterated RatingBuy$1.00High
6/12/2020HC WainwrightReiterated RatingBuy$1.00High
5/14/2020HC WainwrightLower TargetBuy$1.50 ➝ $1.00High
5/11/2020Cantor FitzgeraldReiterated RatingOverweight$2.00 ➝ $1.50Medium
3/26/2020Craig HallumDowngradeBuy ➝ Hold$0.70High
3/26/2020HC WainwrightLower TargetBuy$2.00 ➝ $1.50High
1/21/2020HC WainwrightReiterated RatingBuy$2.00High
11/13/2019HC WainwrightReiterated RatingBuy$2.00High
10/18/2019Cantor FitzgeraldReiterated RatingOverweightHigh
9/27/2019Craig HallumSet TargetBuy$3.00High
8/7/2019HC WainwrightLower TargetBuy$8.00 ➝ $4.00High
6/18/2019HC WainwrightReiterated RatingBuy$8.00High
4/8/2019Cantor FitzgeraldSet TargetBuy$6.00High
3/8/2019Cantor FitzgeraldSet TargetBuy$6.00High
2/20/2019Cantor FitzgeraldReiterated RatingBuy$7.00High
1/14/2019Cantor FitzgeraldReiterated RatingBuy$7.00Medium
12/19/2018HC WainwrightReiterated RatingBuy$8.00High
12/6/2018HC WainwrightSet TargetBuy$8.00Low
11/12/2018Craig HallumInitiated CoverageBuy$8.00Medium
11/12/2018HC WainwrightSet TargetBuy$8.00High
11/9/2018Cantor FitzgeraldReiterated RatingBuy$7.00High
10/24/2018HC WainwrightSet TargetBuy$7.00Medium
9/28/2018HC WainwrightReiterated RatingBuy$7.00High
9/20/2018Cantor FitzgeraldInitiated CoverageBuy$7.00Low
8/22/2018HC WainwrightSet TargetBuy$7.00Low
8/16/2018HC WainwrightReiterated RatingBuy$7.00High
8/6/2018HC WainwrightSet TargetBuy$7.00Medium
7/9/2018SVB LeerinkReiterated RatingOutperformMedium
7/2/2018HC WainwrightSet TargetBuy$7.00Low
6/8/2018HC WainwrightSet TargetBuy$7.00Low
5/22/2018HC WainwrightSet TargetBuy$7.00High
5/14/2018HC WainwrightSet TargetBuy$7.00Low
5/8/2018HC WainwrightSet TargetBuy$7.00Low
4/17/2018HC WainwrightSet TargetBuy$7.00High
3/23/2018HC WainwrightReiterated RatingBuy$7.00High
2/1/2018HC WainwrightReiterated RatingBuy$6.00Medium
1/24/2018HC WainwrightSet TargetBuy$6.00Medium
1/5/2018HC WainwrightSet TargetBuy$6.00High
12/27/2017HC WainwrightSet TargetBuy$6.00High
11/8/2017HC WainwrightReiterated RatingBuy$6.00N/A
9/12/2017HC WainwrightReiterated RatingBuy$6.00High
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/20/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/21/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/20/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/19/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
HTG Molecular Diagnostics logo
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Read More

Today's Range

Now: $0.94
Low: $0.93
High: $1.02

50 Day Range

MA: $6.00
Low: $5.01
High: $6.80

52 Week Range

Now: $0.94
Low: $3.50
High: $7.95

Volume

186,871 shs

Average Volume

918,605 shs

Market Capitalization

$10.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of HTG Molecular Diagnostics?

The following sell-side analysts have issued stock ratings on HTG Molecular Diagnostics in the last year: Cantor Fitzgerald, Craig Hallum, HC Wainwright, StockNews.com, and SVB Leerink LLC.
View the latest analyst ratings for HTGM.

What is the current price target for HTG Molecular Diagnostics?

4 Wall Street analysts have set twelve-month price targets for HTG Molecular Diagnostics in the last year. Their average twelve-month price target is $4.63, suggesting a possible upside of 391.0%. SVB Leerink LLC has the highest price target set, predicting HTGM will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.00 for HTG Molecular Diagnostics in the next year.
View the latest price targets for HTGM.

What is the current consensus analyst rating for HTG Molecular Diagnostics?

HTG Molecular Diagnostics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HTGM will outperform the market and that investors should add to their positions of HTG Molecular Diagnostics.
View the latest ratings for HTGM.

What other companies compete with HTG Molecular Diagnostics?

Other companies that are similar to HTG Molecular Diagnostics include SeqLL, Talis Biomedical, Precipio, China Pharma and Reviva Pharmaceuticals. Learn More about companies similar to HTG Molecular Diagnostics.

How do I contact HTG Molecular Diagnostics' investor relations team?

HTG Molecular Diagnostics' physical mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company's listed phone number is (520) 547-2827. The official website for HTG Molecular Diagnostics is www.htgmolecular.com. Learn More about contacing HTG Molecular Diagnostics investor relations.